Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Age Ageing ; 53(7)2024 Jul 02.
Article in English | MEDLINE | ID: mdl-39051145

ABSTRACT

BACKGROUND: Point of care ultrasound (POCUS) is an imaging technique performed bedside. To date, few published studies have reported the usefulness of multiorgan POCUS in Geriatrics. The objective of this study was to describe the utility of multiorgan POCUS in the care of older adults admitted to geriatric care settings. METHODOLOGY: Observational retrospective study of patients admitted to geriatric settings in Spain and UK. Multiorgan POCUS was performed when there was a specific clinical suspicion or unexplained torpid clinical course despite physical examination and complementary tests. A geriatrician with a certificate degree in comprehensive ultrasound and long-standing experience in POCUS carried out POCUS. All patients underwent multiorgan POCUS in a cephalo-caudal manner. RESULTS: Out of 368 patients admitted to geriatric units, 29% met the inclusion criteria. Average age was 85.9 years (SD ± 6.1). POCUS identified 235 clinically significant findings (2.2 per patient). Findings were classified as 37.9% confirmed diagnosis, 16.6% ruled out diagnosis, 14.9% unsuspected relevant diagnoses and 30.6% clinical follow-ups. POCUS findings led to changes in pharmacological and non-pharmacological treatment in 66.3 and 69.2% respectively, resulted in completion or avoidance of invasive procedures in 17.8 and 15.9%, respectively, facilitating early referrals to other specialities in 14.9% and avoiding transfers in 25.2% of patients. CONCLUSION: Multiorgan POCUS is a tool that aids in the assessment and treatment of patients receiving care in geriatrics units. These results show the usefulness of POCUS in the management of older adults and suggest its inclusion in any curriculum of Geriatric Medicine speciality training.


Subject(s)
Ultrasonography , Humans , Spain , Retrospective Studies , Aged, 80 and over , Male , Female , United Kingdom , Ultrasonography/statistics & numerical data , Ultrasonography/methods , Aged , Point-of-Care Systems , Geriatric Assessment/methods , Geriatrics , Predictive Value of Tests , Age Factors , Point-of-Care Testing/statistics & numerical data , Health Services for the Aged/standards
2.
J Cardiovasc Pharmacol ; 77(1): 22-31, 2021 01 01.
Article in English | MEDLINE | ID: mdl-33136766

ABSTRACT

ABSTRACT: Atrial fibrillation (AF) is associated with an increased risk of dementia. Studies have shown the beneficial effects of anticoagulants in preventing dementia in this population. However, evidence around the use of direct oral anticoagulants (DOACs) versus warfarin in AF-related dementia prevention remains sparse. This systematic review and meta-analysis aimed to evaluate the use of DOACs versus warfarin in dementia prevention in this population. MEDLINE, EMBASE, PsycINFO, and the CENTRAL databases were systematically searched from its inception until May 2020. Nine studies (n = 611,069) were included for quantitative meta-analysis. DOACs use was associated with a lower risk of composite dementia outcomes compared with warfarin use [odds ratio (OR) 0.56, 95% confidence interval (CI) 0.34-0.94, P = 0.03]. No significant difference was found in subtypes of dementia (vascular dementia, Alzheimer's disease, and cognitive disorder) between both groups. No significant difference in the risk of composite dementia outcomes between the dabigatran and warfarin groups (OR 0.97, 95% CI 0.88-1.08, P = 0.61). Apixaban (OR 0.58, 95% CI 0.50-0.67, P < 0.00001) and rivaroxaban (OR 0.67, 95% CI 0.61-0.75, P < 0.00001) use were both associated with a significantly lower risk of composite dementia outcomes compared with warfarin use. Findings need to be interpreted with caution because of low certainty of evidence. In conclusion, this systematic review and meta-analysis of 9 comparative studies demonstrated the superiority of DOACs over warfarin in prevention of dementia in AF. Future prospective trials with adequate follow-up period are warranted to ascertain its causal relationship.


Subject(s)
Anticoagulants/administration & dosage , Antithrombins/administration & dosage , Atrial Fibrillation/drug therapy , Dementia/prevention & control , Factor Xa Inhibitors/administration & dosage , Warfarin/therapeutic use , Administration, Oral , Aged , Aged, 80 and over , Anticoagulants/adverse effects , Antithrombins/adverse effects , Atrial Fibrillation/diagnosis , Atrial Fibrillation/epidemiology , Dementia/diagnosis , Dementia/epidemiology , Factor Xa Inhibitors/adverse effects , Female , Humans , Incidence , Male , Middle Aged , Protective Factors , Risk Assessment , Risk Factors , Time Factors , Treatment Outcome , Warfarin/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL